Neogen Corporation

DB:NG2 Stock Report

Market Cap: €2.2b

Neogen Valuation

Is NG2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NG2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NG2's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NG2's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NG2?

Key metric: As NG2 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NG2. This is calculated by dividing NG2's market cap by their current revenue.
What is NG2's PS Ratio?
PS Ratio2.5x
SalesUS$913.83m
Market CapUS$2.31b

Price to Sales Ratio vs Peers

How does NG2's PS Ratio compare to its peers?

The above table shows the PS ratio for NG2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.9x
PHH2 Paul Hartmann
0.3xn/a€838.2m
EUZ Eckert & Ziegler
4.4x8.8%€1.2b
AFX Carl Zeiss Meditec
2.4x6.3%€5.0b
DRW3 Drägerwerk KGaA
0.3x3.3%€987.9m
NG2 Neogen
2.5x3.9%€2.3b

Price-To-Sales vs Peers: NG2 is expensive based on its Price-To-Sales Ratio (2.5x) compared to the peer average (1.9x).

Price to Sales Ratio vs Industry

How does NG2's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.3x3.3%US$1.02b
PHH2 Paul Hartmann
0.3xn/aUS$865.74m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
NG2 2.5xIndustry Avg. 3.8xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NG2 is good value based on its Price-To-Sales Ratio (2.5x) compared to the European Medical Equipment industry average (3.8x).

Price to Sales Ratio vs Fair Ratio

What is NG2's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NG2 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.5x
Fair PS Ratio1.6x

Price-To-Sales vs Fair Ratio: NG2 is expensive based on its Price-To-Sales Ratio (2.5x) compared to the estimated Fair Price-To-Sales Ratio (1.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NG2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€10.20
€13.44
+31.8%
7.1%€14.40€12.48n/a2
Feb ’26€10.90
€13.44
+23.3%
7.1%€14.40€12.48n/a2
Jan ’26€11.80
€15.19
+28.7%
4.8%€15.91€14.47n/a2
Jan ’25€18.30
€21.16
+15.6%
21.3%€25.68€16.64€11.802
Dec ’24€15.40
€21.16
+37.4%
21.3%€25.68€16.64€13.202
Nov ’24€13.90
€21.16
+52.2%
21.3%€25.68€16.64€12.902
Oct ’24€17.30
€24.30
+40.5%
7.7%€26.17€22.43€14.902
Sep ’24€21.20
€23.75
+12.0%
7.7%€25.58€21.92€15.302
Aug ’24€20.40
€18.69
-8.4%
7.3%€20.06€17.32€15.602
Jul ’24€20.00
€18.74
-6.3%
7.3%€20.11€17.37€14.402
Analyst Price Target
Consensus Narrative from 2 Analysts
€13.77
Fair Value
25.9% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 23:47
End of Day Share Price 2025/02/07 00:00
Earnings2024/11/30
Annual Earnings2024/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neogen Corporation is covered by 18 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David WestenbergCL King & Associates, Inc.
Steven CrowleyCraig-Hallum Capital Group LLC
Paul KnightCredit Agricole Securities (USA) Inc.